Trial
NCT00632541
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Hoosier Cancer Research Network
Collaborators
Genentech, Inc.; Bayer; Amgen
Condition
Metastatic Breast Cancer
Intervention
Sorafenib
Why stopped
Significant Toxicities Experienced
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-14